On August 4, 2026 Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, reported a new CEO Corner segment featuring President and Chief Executive Officer Abizer Gaslightwala discussing the Company’s recently announced strategic research collaboration with WhiteHawk Therapeutics and why the Company believes scientifically driven collaborations will play an increasingly important role in advancing the next generation of ADC innovation.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In the segment, Mr. Gaslightwala discusses how the ADC landscape continues to evolve beyond the development of individual payload technologies toward collaborative strategies designed to combine complementary mechanisms of action. He explains why Akari believes bringing together differentiated scientific approaches has the potential to accelerate innovation, generate meaningful translational insights and expand future therapeutic opportunities beyond what may be achieved through a single technology alone.
At the center of the discussion is Akari’s recently announced strategic research collaboration with WhiteHawk Therapeutics, which combines Akari’s proprietary PH1 spliceosome-modulating payload with WhiteHawk’s differentiated TOP1 inhibitor ADC platform to evaluate a novel dual-payload strategy. Mr. Gaslightwala explains why the Company believes evaluating two potentially best-in-class payload technologies together represents an innovative scientific approach with the potential to broaden therapeutic activity while further demonstrating the versatility and broad applicability of Akari’s PH1 platform.
Beyond the collaboration itself, the CEO Corner explores the growing pharmaceutical industry interest in differentiated payload technologies capable of addressing important unmet needs across oncology. Mr. Gaslightwala discusses how strategic collaborations can provide additional opportunities to expand scientific validation of novel payload platforms while creating new pathways for innovation through partnerships with organizations that share a common vision for advancing ADC science.
Looking ahead, Mr. Gaslightwala outlines Akari’s continued focus on advancing AKTX-101, the Company’s lead TROP2-targeting ADC, toward planned Phase 1 clinical evaluation while continuing to expand the scientific foundation supporting its proprietary PH1 spliceosome-modulating payload platform. He emphasizes that the Company’s internal development programs and strategic collaborations represent complementary components of a broader strategy to establish PH1 as a differentiated payload platform with the potential to support multiple future therapeutic applications.
(Press release, Akari Therapeutics, AUG 4, 2026, View Source [SID1234669652])